Ultrasensitive Immunoassay for Early Screening of Non-Small Cell
Lung Cancer via Biomarkers in Tumor-Derived Extracellular Vesicles
Lung cancer (LC), particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related deaths worldwide. Early diagnosis is critical, as survival rates for stage I NSCLC can reach 85%, compared to just 15–19% for late-stage diagnoses. However, current screening methods, such as low dose computed tomography (LDCT), face significant limitations, including high costs, radiation risks, and false positives. This highlights the urgent need for innovative, non-invasive, and cost-effective screening alternatives.
ONCOSOMIX addresses this need by developing an ultrasensitive point-of-care (PoC) diagnostic test targeting biomarkers in tumor-derived extracellular vesicles (oncosomes). Extracellular vesicles (EVs), found in body fluids, contain biomolecules that reflect the physiological state of their parent cells, making them ideal for non-invasive cancer screening. Leveraging advanced technologies like nanoparticle-enhanced lateral flow immunoassays (LFIA), ONCOSOMIX aims to achieve comparable screening sensitivity with lower cost and easier access than results from LDCT
ONCOSOMIX has the potential to change lung cancer diagnostics, quadrupling early detection rates by extending screening to all high-risk population at a lower cost and higher accessibility screening when compared with LDCT
Project Budget: 1.977.771 €
Linkcare total funding: 1.018.687 €
Financial Framework: Plan Estatal De Investigación Científica, Técnica Y De Innovación 2024 – 2027
Start Date: 01/10/2025
End Date: 30/12/2028
Contract number: CPP2024-011652
Grant CPP2024-011652 funded by:
Contact Us